We found that knockdown of MCL1, and to a lesser extent BCLXL, sensitized cells to treatment with AZA up to a dose of 2.5 uM, indicating that a combination of MCL1 or BCLXL inhibition with AZA treatment may be an effective combination in melanoma (Figure 2A,B). The gene discussed is MCL1; the disease is melanoma.